Results 171 to 180 of about 18,591,271 (238)
Addiction, EarlyView.Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria +10 more
wiley +1 more source
Cannabis use and cannabis use disorder among older adults in the USA
Addiction, EarlyView.Abstract Background and aims Cannabis use is increasing among older adults in the United States (US); however, little is known regarding details of use or cannabis use disorder (CUD) in this population. This study aimed to describe cannabis use and CUD among older adults in the US.
Benjamin H. Han +4 more
wiley +1 more source
Addiction, EarlyView.Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke +5 more
wiley +1 more source
Addiction, EarlyView.Abstract Aims ‘Mad honey’ is produced when bees collect nectar from Rhododendron species containing grayanotoxins, naturally occurring diterpenoid toxins that can produce dose‐dependent intoxication. It has long been embedded in Nepalese medicinal and ritual practices but has recently become part of global psychedelic discourse. This study examined how
Sharon R. Sznitman, Surendra Tiwari
wiley +1 more source
Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review
The American Journal on Addictions, EarlyView.Abstract Background and Objectives Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS.
Faizan Khan +2 more
wiley +1 more source
The American Journal on Addictions, EarlyView.Abstract Background and Objectives Cannabis withdrawal symptoms can be severe and protracted, significantly impeding the ability to abstain from cannabis use, resulting in failed quit attempts and relapse. This clinical trial evaluated safety and efficacy of PP‐01, a novel dual‑mechanism of action, investigational agent, for mitigating cannabis ...
Ashley F. Slagle +4 more
wiley +1 more source
The Need for a Global Registry for Charting the Natural History of Klinefelter Syndrome
Andrology, EarlyView.ABSTRACT Background Although Klinefelter Syndrome (KS) represents the most common sex chromosome aneuploidy, several gaps in knowledge persist regarding optimal management of individuals with this condition. Individuals with KS can have a diverse phenotype including endocrine, neurodevelopmental, and cardiovascular manifestations.
Malika Alimussina +13 more
wiley +1 more source
ANZ Journal of Surgery, EarlyView.ABSTRACT Background Poor reporting of baseline descriptor, diversity and inclusion data is a barrier in surgical research for drawing generalisable conclusions across diverse populations. Post‐operative ileus was used as an exemplar surgical condition to quantify the variation in baseline descriptor, inclusivity and diversity data in randomised ...
Miriam Khalil +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr +10 more
wiley +1 more source